Download PDF
Aktuelle Dermatologie 2013; 39(07): 278-282
DOI: 10.1055/s-0033-1344197
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Lasertherapie der Onychomykose: Aktueller Stand

Laser Treatment of Onychomycosis: State of the Art
H. Hees
1   Laserklinik Karlsruhe
,
C. Raulin
1   Laserklinik Karlsruhe
2   Hautklinik der Universität Heidelberg
› Author Affiliations
Further Information

Publication History

Publication Date:
10 July 2013 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die Therapie des Nagelpilzes beschränkte sich bislang auf antimykotische Externa und die systemische Therapie. Die zunehmend durchgeführte Lasertherapie könnte die Behandlung der Onychomykose richtungsweisend verändern. Die verfügbaren Lasersysteme werden mit kurzen Behandlungszeiten, Nebenwirkungsfreiheit und hoher Effektivität beworben. Nach Zulassung der meisten Geräte durch die FDA (U.S. Food and Drug Administration) steht dem flächendeckenden Einsatz nichts mehr im Wege. Demgegenüber steht eine fehlende Evidenz durch klinische Studien von guter wissenschaftlicher Qualität.

Im Folgenden werden die verfügbaren Geräte samt publizierter Studien zusammenfassend vorgestellt und kritisch diskutiert.

Abstract

Antimycotic ointment and systemic therapy have been the state of the art treatment of nail fungus for years. Since laser therapy has recently been performed on a larger scale, it could give direction to onychomycosis treatment in the future. The available laser systems are advertised with considerable advantages: short time of treatment, no adverse effects, complete nail clearance after a few sessions. Most of the devices are FDA (U.S. Food and Drug Administration) approved but the lack of evidence and clinical trials that were published in influential journals tarnish the positive image.

In this overview available laser devices and published research studies are presented and discussed in a critical manner.

 

  • Literatur

  • 1 Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-648
    CrossrefPubMedGoogle Scholar
  • 2 Schlefman BS. Onychomycosis: a compendium of facts and a clinical experience. J Foot Ankle Surg 1999; 38: 290-302
    PubMedGoogle Scholar
  • 3 Drake LA, Patrick DL, Fleckman P et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999; 41: 189-196
    CrossrefPubMedGoogle Scholar
  • 4 Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998; 38: 32-36
    CrossrefPubMedGoogle Scholar
  • 5 Zaias N, Glick B, Rebell G. Diagnosing and treating onychomycosis. J Fam Pract 1996; 42: 513-518
    PubMedGoogle Scholar
  • 6 Gupta AK, Drummond-Main C, Cooper EA et al. Systematic review of nondermatophyte mold onychomycosis: Diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol 2012; 66: 494-502
    CrossrefPubMedGoogle Scholar
  • 7 Albert SF, Weis ZH. Management of onychomycosis with topicals. Clin Podiatr Med Surg 2004; 21: 605-615 vii
    CrossrefPubMedGoogle Scholar
  • 8 Bodman MA, Feder L, Nace AM. Topical treatments for onychomycosis: a historical perspective. J Am Podiatr Med Assoc 2003; 93: 136-141
    PubMedGoogle Scholar
  • 9 Brenner MA, Harkless LB, Mendicino RW et al. Ciclopirox 8 % nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study. J Am Podiatr Med Assoc 2007; 97: 195-202
    PubMedGoogle Scholar
  • 10 Tosti A, Piraccini BM, Stinchi C et al. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998; 197: 162-166
    CrossrefPubMedGoogle Scholar
  • 11 Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007; 20: 31-46
    CrossrefPubMedGoogle Scholar
  • 12 De Doncker P, Decroix J, Pierard GE et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132: 34-41
    CrossrefPubMedGoogle Scholar
  • 13 Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010; 62: 411-414
    CrossrefPubMedGoogle Scholar
  • 14 Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. J Drugs Dermatol 2010; 9: 1109-1113
    PubMedGoogle Scholar
  • 15 Gupta A, Simpson F. Device-based therapies for onychomycosis treatment. Skin Therapy Lett 2012; 17: 4-9
    PubMedGoogle Scholar
  • 16 Gupta AK, Simpson F. Newly approved laser systems for onychomycosis. J Am Podiatr Med Assoc 2012; 102: 428-430
    PubMedGoogle Scholar
  • 17 Altshuler GB, Anderson RR, Manstein D et al. Extended theory of selective photothermolysis. Lasers Surg Med 2001; 29: 416-432
    CrossrefPubMedGoogle Scholar
  • 18 Emyanitoff RG, Hashimoto T. The effects of temperature, incubation atmosphere, and medium composition on arthrospore formation in the fungus Trichophyton mentagrophytes. Can J Microbiol 1979; 25: 362-366
    CrossrefPubMedGoogle Scholar
  • 19 Hashimoto T, Blumenthal HJ. Survival and resistance of Trichophyton mentagrophytes arthrospores. Appl Environ Microbiol 1978; 35: 274-277
    PubMedGoogle Scholar
  • 20 Bornstein E, Hermans W, Gridley S et al. Near-infrared photoinactivation of bacteria and fungi at physiologic temperatures. Photochem Photobiol 2009; 85: 1364-1374
    CrossrefPubMedGoogle Scholar
  • 21 Raulin C, Kimmig W, Werner S. [Laser therapy in dermatology and esthetic medicine. Side effects, complications and treatment errors]. Hautarzt 2000; 51: 463-473
    CrossrefPubMedGoogle Scholar
  • 22 Manevitch Z, Lev D, Hochberg M et al. Direct antifungal effect of femtosecond laser on Trichophyton rubrum onychomycosis. Photochem Photobiol 2009; 86: 476-479
    PubMedGoogle Scholar
  • 23 Landsman AS, Robbins AH. Treatment of Mild, Moderate, and Severe Onychomycosis Using 870- and 930-nm Light Exposure: Some Follow-up Observations at 270 Days. J Am Podiatr Med Assoc 2012; 102: 169-171
    PubMedGoogle Scholar
  • 24 Landsman AS, Robbins AH, Angelini PF et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc 2010; 100: 166-177
    PubMedGoogle Scholar
  • 25 Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther 2011; 13: 2-5
    CrossrefPubMedGoogle Scholar
  • 26 Kozarev J, Vizintin Z. Novel laser therapy in treatment of onychomycosis. Journal of the Laser and Health Academy 2010; 1-8
    PubMedGoogle Scholar
  • 27 Zhang RN, Wang DK, Zhuo FL et al. Long-pulse Nd:YAG 1064-nm laser treatment for onychomycosis. Chin Med J (Engl) 2012; 125: 3288-3291
    PubMedGoogle Scholar
  • 28 Weiss D. 3 month clinical results using sub-millisecond 1064 nm Nd:YAG laser for the treatment of oynchomycosis. Available at: http://conejofeet.com/wp-content/uploads/2011/06/David-Weiss-DPM-report.pdf Dem Internet entnommen im August 2012.
    PubMedGoogle Scholar
  • 29 Kimura U, Takeuchi K, Kinoshita A et al. Treating Onychomycoses of the Toenail: Clinical Efficacy of the Sub-Millisecond 1,064 nm Nd:YAG Laser Using a 5 mm Spot Diameter. J Drugs Dermatol 2012; 11: 496-504
    PubMedGoogle Scholar
  • 30 VwG Arnsberg. Beschl. vom 8. 5. 2012. 3L247/12.
    PubMedGoogle Scholar